Key Highlights

  • Revenue for the 15 months to 31 March 2026 was £4.9m, with the operating loss widening to £2.9m.
  • A fundraise raised approximately £10.8m gross at 4.0p per share, taking post-raise cash to around £9.0m.
  • An insecticide licensing agreement is expected to be signed by the end of 2026, with partners narrowed to a small number.
  • Approvals in the period spanned California, France, Slovakia, Egypt and Chile.

Eden Research plc (LSE:EDEN), the Oxfordshire biopesticide developer, has just closed the most eventful reporting period in its recent history with preliminary results that the wider market has barely registered. Published on 26 August 2026, the numbers cover an unusual 15-month stretch to 31 March 2026, reflecting a change of year end designed to match the growing season of the vineyards that use its products.

The headline figures are modest: Revenue of £4.9m and a pre-tax loss of £2.9m. What matters more sits behind them. A £10.8m fundraise completed in April, a first distribution deal with Syngenta, product approvals from California to Egypt, and a promised insecticide licensing agreement by the end of 2026 set up a year in which the company's £17m Market Value could look very different, in either direction.

Preliminary results for the 15 months to 31 March 2026: a longer year, a bigger loss, a refilled balance sheet

Revenue for the 15 months to 31 March 2026 was £4.9m against £4.3m for the 12 months to 31 December 2024, with Gross Profit of £2.2m against £1.9m. Eden cautions that the periods "are not directly comparable" given the extended window and seasonal sales timing. The operating loss widened to £2.9m from £2.2m, the loss after tax was £2.5m against £1.9m, and basic loss per share was 0.45p compared with 0.36p. The outcome matched the 28 April 2026 trading update, which guided to results "broadly in line with market expectations" of £5.0m revenue and a £2.8m pre-tax loss.

Period-end cash of £1.5m, down from £3.7m, predates the second Tranche of the fundraise. Eden raised approximately £10.8m gross at 4.0p per share: roughly £3.2m arrived before the year end and £7.6m on 13 April 2026, when 190 million new shares were admitted to AIM. The April update put post-fundraise cash at around £9.0m, and the directors forecast a positive cash balance "throughout the entire forecast period" under both base and downside scenarios.

Chief executive Sean Smith said the company "has never been better positioned", adding that "the structural shift away from conventional chemistry is accelerating; our marketed products are winning approvals and taking share in important existing and new geographies."

What Eden Research does

Eden is built around two proprietary platforms. The first is terpene chemistry: naturally occurring plant compounds such as thymol that act as fungicides, insecticides and nematicides. The second is Sustaine, a plastic-free microencapsulation system using biodegradable yeast-derived micro-spheres to control the release of those volatile actives. The company calls Sustaine "one of the only viable, proven and immediately registerable solutions to the microplastics problem" in crop protection.

Its flagship product is Mevalone, a botrytis fungicide sold as 3LOGY or Trilogy in some territories and used mainly on grapes. Cedroz is a nematicide, Novellus+ a fungicide newly approved in Chile, Ecovelex a maize seed treatment with temporary authorisation in Italy, and Evelta the fungicide Syngenta will distribute to ornamental growers. Beyond agriculture, Eden supplies encapsulated thymol to Véto-pharma for Thymolflex, a bee-health treatment that received US EPA approval on 2 April 2026.

Eden does not sell to growers directly. It owns the registrations and supplies partners such as Sipcam, Biocont, Andermatt and now Syngenta, which market the products territory by territory. Sales are concentrated in southern European viticulture and depend on weather: wet seasons drive demand, while hot, dry conditions reduce usage.

Financial performance in detail

The 15-month period produced a gross Margin of roughly 45% on revenue of £4.9m and an EBITDA loss of £1.7m, according to the April trading update. Cash absorbed by operations was £3.1m, partly offset by a £0.6m development tax credit. Net Assets rose to £12.4m from £11.8m. Eden pays no dividend.

The fundraise was dilutive. Issued Share Capital rose to 803.4 million shares after the April placing, and the 4.0p issue price now sits well above the market. On 2 September 2026 the shares stood at 2.15p, a Market Capitalisation of roughly £17m, against a 52-week high of 4.95p in January and a low of 2.00p on 13 August 2026. Guidance for the year to 31 March 2027 is thin: the board said its expectation "currently remains unchanged", subject to Mevalone stocking ahead of the 2027 season and the timing of Ecovelex approvals.

What could drive the stock next?

The largest catalyst is the insecticide. Eden says it has narrowed potential licensing partners for its first insecticide, targeting spider mites, whitefly, aphids and thrips, to "a small number" and expects to sign an agreement "by the end of 2026". A deal with a major agrochemical group would validate the platform and could bring upfront payments.

Regulatory momentum is the second driver. In the past year Mevalone has been approved in California, France and Slovakia, Trilogy in Egypt and Novellus+ in Chile. The 4 August 2026 announcement highlighted Egypt's position as the world's second-largest table grape producer and the advantage of a fungicide with no pre-harvest interval for growers exporting to Europe. Registrations in Algeria, Tunisia and Morocco are being pursued, and full European authorisation for Ecovelex is a stated priority.

The Syngenta relationship, announced on 18 December 2025, is a third: Eden's first agreement with one of the world's largest crop protection groups, with Syngenta funding the efficacy data needed for registration. A late-blight fungicide for potatoes and a Septoria programme for wheat would, if successful, take Eden into broad-acre crops for the first time.

Risks investors should watch

Eden has been loss-making for years and remains dependent on external capital. Operating cash outflow of £3.1m over 15 months against roughly £9.0m of post-placing cash implies a runway of a few years unless revenue grows or a licensing deal delivers cash. Any future raise near the current 2.15p would be far more dilutive than the 4.0p placing.

Revenue is small, seasonal and weather-dependent, and concentrated in a handful of distributors and one crop. The insecticide deal is a negotiation, not a contract, and full EU authorisation of Ecovelex is slow and uncertain. The board lost its audit committee chair, Derek McAllan, to ill health on 27 May 2026, with Rob Cridland serving as interim chair. With a 15% bid-offer spread and thin volumes, the shares can move sharply on little news.

Outlook

Eden Research (LSE:EDEN) enters its new financial year with more cash, more approvals and a broader partner base than before, but with a share price that has roughly halved since the placing was priced. Commercial progress has not yet produced a materially larger revenue line, and the first full year under the March year end will be a clearer test than the transition period.

The items to monitor are concrete: whether the insecticide agreement is signed by the end of 2026 and on what terms, the pace of Mevalone stocking for the 2027 season, progress on Ecovelex in Europe, and first sales from Egypt and Slovakia. If those milestones land, the gap between operational momentum and a £17m valuation may narrow; if they slip, the funding question will return sooner than management would like.